Messenger RNA (mRNA)-based technologies have emerged as transformative tools in modern medicine, particularly in vaccine development and cellular immunotherapy. This research article provides a comprehensive and theoretically enriched analysis of mRNA-based vaccines and RNA-engineered T cell therapeutics, grounded strictly in regulatory frameworks and experimental studies referenced in the European Pharmacopoeia and seminal molecular therapy literature. The study explores the structural, functional, and translational dynamics of mRNA substances, DNA templates, and vaccine constructs, alongside advancements in RNA electroporation for T cell modification. Emphasis is placed on the dual paradigm of transient and stable expression systems in therapeutic design, highlighting their implications in oncology and infectious disease management. The methodology adopts an integrative analytical approach, synthesizing regulatory standards with experimental findings to derive conceptual models of efficacy, safety, and scalability. Results indicate that while mRNA platforms offer unparalleled flexibility and rapid adaptability, challenges persist in delivery optimization, immune modulation, and long-term stability. The discussion critically evaluates these limitations, proposing future directions in nanotechnology, regulatory harmonization, and personalized medicine. This article contributes to the growing body of knowledge by bridging pharmacopoeial guidelines with translational research, offering a nuanced perspective on the future trajectory of mRNA-based therapeutics.

mRNA vaccines, RNA electroporation, T cell engineering, mmunotherapy, lipid nanoparticles, gene expression, regulatory standards

Pardi, N., Hogan, M. J., Porter, F. W., & Weissman, D. (2018). mRNA vaccines—a new era in vaccinology. Nature Reviews Drug Discovery, 17, 261–279.

Sahin, U., et al. (2020). COVID-19 mRNA vaccine development. Nature, 586, 567–571.

June, C. H., O’Connor, R. S., Kawalekar, O. U., Ghassemi, S., & Milone, M. C. (2018). CAR T cell immunotherapy for human cancer. Science, 359, 1361–1365.

Wang, Z., et al. (2022). mRNA-based CAR-T cell therapies: Current status. Frontiers in Immunology, 13, 873541.

Krammer, F. (2020). SARS-CoV-2 vaccines in development. Nature, 586, 516–527.

Verbeke, R., et al. (2021). The dawn of mRNA vaccines: Advances and challenges. Molecular Therapy, 29, 2485–2501.

Sahin, U., Karikó, K., & Türeci, Ö. (2014). mRNA-based therapeutics—developing a new class of drugs. Nature Reviews Drug Discovery, 13, 759–780.

Maus, M. V., & June, C. H. (2016). Making better CARs. Nature Reviews Cancer, 16, 165–176.

Schlake, T., Thess, A., Fotin-Mleczek, M., & Kallen, K. J. (2012). Developing mRNA-vaccine technologies. RNA Biology, 9, 1319–1330.

1He, X., et al. (2021). RNA therapeutics in cancer immunotherapy. Trends in Molecular Medicine, 27, 1014–1027.